March 27 (Reuters) - Highlights of the day for U.S. President Donald Trump's administration on Monday:
A Russian bank under Western economic sanctions over Russia's incursion into Ukraine discloses that its executives had met Jared Kushner, Trump's son-in-law and a top White House adviser, during the 2016 election campaign.
Kushner, already a White House senior adviser, will take on the additional task of overseeing an effort to overhaul the federal government, the White House says.
Representative Adam Schiff, the top Democrat on the House of Representatives' Intelligence Committee, says committee Chairman Devin Nunes should recuse himself from any further involvement in the panel's investigation of Russian involvement in the 2016 election.
Nunes says he did not meet with Trump or his aides when he viewed intelligence information on the White House grounds last week.
Following the failure of the healthcare bill that Trump backed, his administration plans to take a lead role in crafting major legislation to cut taxes with an eye toward meeting an August target date, the White House says.
The Republican-controlled House will not seek to repeal Obamacare taxes as a part of expected tax reform legislation, the top House Republican on tax policy says.
SUPREME COURT NOMINEE
Democratic opposition to Trump's U.S. Supreme Court nominee grows while the White House demands a "fair up-or-down vote" in the Senate on confirming Neil Gorsuch to the lifetime post.
Stocks, the dollar and U.S. long-dated Treasury yields steady after sharp drops, as investors hope Trump will be able to bolster the economy despite a defeat over healthcare reform.
American cities that do not cooperate with federal immigration authorities may lose millions of dollars in grant money from the Justice Department, U.S. Attorney General Jeff Sessions says.
Several Democratic senators press billionaire investor Carl Icahn to clarify his role as an adviser to Trump on regulation, saying his position in the administration raises "alarming" questions about potential conflicts of interest with his stakes in the biofuels and pharmaceutical industries.
Top heart doctors and researchers have a simple reaction to Trump's proposed 20 percent cut to the budget of the U.S. National Institutes of Health: fear that research that results in lifesaving drugs will be dealt a crippling blow.
(Compiled by Bill Trott and Jonathan Oatis; Editing by Peter Cooney and Leslie Adler)